Trial reportJournal of gynecologic oncology2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.
Trial report in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04482309 (A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
Who cites it
4 citing papers in PubMed.
- Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases.Cancers · 2026Article
- Endometrial cancer molecular classification: research advances and clinical application.Frontiers in oncology · 2026Review
- Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them.Frontiers in immunology · 2026Review
- Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies.Therapeutic advances in medical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveTo investigate antitumor activity, safety, and exploratory subgroup analyses for trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+ and 2+) gynecologic cancers.
methodsDESTINY-PanTumor02 is a 2-part, open-label, multicenter, phase 2 study. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing solid tumors received T-DXd 5.4 mg/kg. Primary endpoint was investigator-assessed (INV) confirmed objective response rate (ORR). Secondary endpoints included safety, ORR by independent central review (ICR), progression-free survival, and overall survival. Exploratory endpoints included ORRs by biomarker status. This analysis reports data from the endometrial, cervical, and ovarian cancer cohorts.
resultsAt primary analysis data cutoff, 120 patients received treatment across 3 gynecologic cancer cohorts. Median follow-up (range) was 19.9 months (0.8-31.1), 12.6 months (0.9-31.0), and 13.1 months (0.7-30.6) in the endometrial, cervical, and ovarian cancer cohorts, respectively. INV confirmed ORRs (n/N [95% confidence interval]) in the endometrial, cervical, and ovarian cancer cohorts were 57.5% (23/40 [40.9-73.0]), 50.0% (20/40 [33.8-66.2]), and 45.0% (18/40 [29.3-61.5]), respectively, and by ICR were 57.5% (23/40 [40.9-73.0]), 37.5% (15/40 [22.7-54.2]), and 42.5% (17/40 [27.0-59.1]), respectively. ORRs were highest for the HER2 IHC 3+ populations. Although patient numbers were small in some subgroups, objective responses were observed regardless of tumor histology, prior treatment, and biomarker expression/mutation status. Adjudicated interstitial lung disease/pneumonitis occurred in 13 patients (10.8%; Grade 1, n=4; Grade 2, n=8; Grade 5, n=1).
conclusionT-DXd induced clinically meaningful ORRs, with safety consistent with the known profile. Data further support T-DXd as a therapeutic option for pretreated HER2-expressing gynecologic cancers.
trial registrationClinicalTrials.gov Identifier: NCT04482309.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.